Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response.

Guo T, Dakkak D, Rodriguez-Martin T, Noble W, Hanger DP.

Acta Neuropathol Commun. 2019 Jan 3;7(1):2. doi: 10.1186/s40478-018-0651-9.

2.

Characterisation of tau in the human and rodent enteric nervous system under physiological conditions and in tauopathy.

Lionnet A, Wade MA, Corbillé AG, Prigent A, Paillusson S, Tasselli M, Gonzales J, Durieu E, Rolli-Derkinderen M, Coron E, Duchalais E, Neunlist M, Perkinton MS, Hanger DP, Noble W, Derkinderen P.

Acta Neuropathol Commun. 2018 Jul 23;6(1):65. doi: 10.1186/s40478-018-0568-3.

3.

A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.

Giacomini C, Koo CY, Yankova N, Tavares IA, Wray S, Noble W, Hanger DP, Morris JDH.

Acta Neuropathol Commun. 2018 May 7;6(1):37. doi: 10.1186/s40478-018-0539-8.

4.

Hippocampal neurophysiology is modified by a disease-associated C-terminal fragment of tau protein.

Tamagnini F, Walsh DA, Brown JT, Bondulich MK, Hanger DP, Randall AD.

Neurobiol Aging. 2017 Dec;60:44-56. doi: 10.1016/j.neurobiolaging.2017.07.005. Epub 2017 Jul 20.

5.

The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Sanz-Blasco S, Bordone MP, Damianich A, Gomez G, Bernardi MA, Isaja L, Taravini IR, Hanger DP, Avale ME, Gershanik OS, Ferrario JE.

Mol Neurobiol. 2018 Jun;55(6):5125-5136. doi: 10.1007/s12035-017-0748-3. Epub 2017 Aug 24.

PMID:
28840468
6.

Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease.

Croft CL, Kurbatskaya K, Hanger DP, Noble W.

Sci Rep. 2017 Aug 7;7(1):7434. doi: 10.1038/s41598-017-07906-1.

7.

Roles of tau protein in health and disease.

Guo T, Noble W, Hanger DP.

Acta Neuropathol. 2017 May;133(5):665-704. doi: 10.1007/s00401-017-1707-9. Epub 2017 Apr 6. Review.

8.

α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production.

Paillusson S, Gomez-Suaga P, Stoica R, Little D, Gissen P, Devine MJ, Noble W, Hanger DP, Miller CCJ.

Acta Neuropathol. 2017 Jul;134(1):129-149. doi: 10.1007/s00401-017-1704-z. Epub 2017 Mar 23.

9.

Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures.

Croft CL, Wade MA, Kurbatskaya K, Mastrandreas P, Hughes MM, Phillips EC, Pooler AM, Perkinton MS, Hanger DP, Noble W.

Cell Death Dis. 2017 Mar 16;8(3):e2671. doi: 10.1038/cddis.2017.97.

10.

The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy.

Gomez-Suaga P, Paillusson S, Stoica R, Noble W, Hanger DP, Miller CCJ.

Curr Biol. 2017 Feb 6;27(3):371-385. doi: 10.1016/j.cub.2016.12.038. Epub 2017 Jan 26.

11.

ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations.

Stoica R, Paillusson S, Gomez-Suaga P, Mitchell JC, Lau DH, Gray EH, Sancho RM, Vizcay-Barrena G, De Vos KJ, Shaw CE, Hanger DP, Noble W, Miller CC.

EMBO Rep. 2016 Sep;17(9):1326-42. doi: 10.15252/embr.201541726. Epub 2016 Jul 14.

12.

Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.

Bondulich MK, Guo T, Meehan C, Manion J, Rodriguez Martin T, Mitchell JC, Hortobagyi T, Yankova N, Stygelbout V, Brion JP, Noble W, Hanger DP.

Brain. 2016 Aug;139(Pt 8):2290-306. doi: 10.1093/brain/aww137. Epub 2016 Jun 12.

13.

Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.

Lau DH, Hogseth M, Phillips EC, O'Neill MJ, Pooler AM, Noble W, Hanger DP.

Acta Neuropathol Commun. 2016 May 18;4(1):49. doi: 10.1186/s40478-016-0317-4.

14.

Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.

Kurbatskaya K, Phillips EC, Croft CL, Dentoni G, Hughes MM, Wade MA, Al-Sarraj S, Troakes C, O'Neill MJ, Perez-Nievas BG, Hanger DP, Noble W.

Acta Neuropathol Commun. 2016 Mar 31;4:34. doi: 10.1186/s40478-016-0299-2.

15.

Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice.

Gilley J, Ando K, Seereeram A, Rodríguez-Martín T, Pooler AM, Sturdee L, Anderton BH, Brion JP, Hanger DP, Coleman MP.

Neurobiol Aging. 2016 Mar;39:1-18. doi: 10.1016/j.neurobiolaging.2015.11.028. Epub 2015 Dec 7.

16.

Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons.

Rodríguez-Martín T, Pooler AM, Lau DHW, Mórotz GM, De Vos KJ, Gilley J, Coleman MP, Hanger DP.

Neurobiol Dis. 2016 Jan;85:1-10. doi: 10.1016/j.nbd.2015.10.007. Epub 2015 Oct 11.

17.

Astrocytes and neuroinflammation in Alzheimer's disease.

Phillips EC, Croft CL, Kurbatskaya K, O'Neill MJ, Hutton ML, Hanger DP, Garwood CJ, Noble W.

Biochem Soc Trans. 2014 Oct;42(5):1321-5. doi: 10.1042/BST20140155.

PMID:
25233410
18.

Intracellular and extracellular roles for tau in neurodegenerative disease.

Hanger DP, Lau DH, Phillips EC, Bondulich MK, Guo T, Woodward BW, Pooler AM, Noble W.

J Alzheimers Dis. 2014;40 Suppl 1:S37-45. doi: 10.3233/JAD-132054. Review.

PMID:
24595196
19.

Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3β.

Povellato G, Tuxworth RI, Hanger DP, Tear G.

Biol Open. 2014 Jan 15;3(1):1-11. doi: 10.1242/bio.20136692.

20.

A role for tau at the synapse in Alzheimer's disease pathogenesis.

Pooler AM, Noble W, Hanger DP.

Neuropharmacology. 2014 Jan;76 Pt A:1-8. doi: 10.1016/j.neuropharm.2013.09.018. Epub 2013 Sep 25. Review.

PMID:
24076336
21.

Calpain cleavage and inactivation of the sodium calcium exchanger-3 occur downstream of Aβ in Alzheimer's disease.

Atherton J, Kurbatskaya K, Bondulich M, Croft CL, Garwood CJ, Chhabra R, Wray S, Jeromin A, Hanger DP, Noble W.

Aging Cell. 2014 Feb;13(1):49-59. doi: 10.1111/acel.12148. Epub 2013 Sep 18.

22.

The importance of tau phosphorylation for neurodegenerative diseases.

Noble W, Hanger DP, Miller CC, Lovestone S.

Front Neurol. 2013 Jul 1;4:83. doi: 10.3389/fneur.2013.00083. eCollection 2013.

23.

Tau phosphorylation affects its axonal transport and degradation.

Rodríguez-Martín T, Cuchillo-Ibáñez I, Noble W, Nyenya F, Anderton BH, Hanger DP.

Neurobiol Aging. 2013 Sep;34(9):2146-57. doi: 10.1016/j.neurobiolaging.2013.03.015. Epub 2013 Apr 17.

24.

Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease.

Tavares IA, Touma D, Lynham S, Troakes C, Schober M, Causevic M, Garg R, Noble W, Killick R, Bodi I, Hanger DP, Morris JD.

J Biol Chem. 2013 May 24;288(21):15418-29. doi: 10.1074/jbc.M112.448183. Epub 2013 Apr 12.

25.

Physiological release of endogenous tau is stimulated by neuronal activity.

Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP.

EMBO Rep. 2013 Apr;14(4):389-94. doi: 10.1038/embor.2013.15. Epub 2013 Feb 15.

26.

NUB1 modulation of GSK3β reduces tau aggregation.

Richet E, Pooler AM, Rodriguez T, Novoselov SS, Schmidtke G, Groettrup M, Hanger DP, Cheetham ME, van der Spuy J.

Hum Mol Genet. 2012 Dec 15;21(24):5254-67. doi: 10.1093/hmg/dds376. Epub 2012 Sep 10.

PMID:
22965877
27.

Key issues in the acquisition and analysis of qualitative and quantitative mass spectrometry data for peptide-centric proteomic experiments.

Thompson AJ, Abu M, Hanger DP.

Amino Acids. 2012 Sep;43(3):1075-85. doi: 10.1007/s00726-012-1287-x. Epub 2012 Jul 22. Review.

PMID:
22821266
28.

Advances in tau-based drug discovery.

Noble W, Pooler AM, Hanger DP.

Expert Opin Drug Discov. 2011 Aug 1;6(8):797-810.

29.

Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation.

Hanger DP, Noble W.

Int J Alzheimers Dis. 2011;2011:352805. doi: 10.4061/2011/352805. Epub 2011 Jul 11.

30.

Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.

Usardi A, Pooler AM, Seereeram A, Reynolds CH, Derkinderen P, Anderton B, Hanger DP, Noble W, Williamson R.

FEBS J. 2011 Aug;278(16):2927-37. doi: 10.1111/j.1742-4658.2011.08218.x. Epub 2011 Jul 7.

31.

Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture.

Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W.

Cell Death Dis. 2011 Jun 2;2:e167. doi: 10.1038/cddis.2011.50.

32.

Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse.

Gilley J, Seereeram A, Ando K, Mosely S, Andrews S, Kerschensteiner M, Misgeld T, Brion JP, Anderton B, Hanger DP, Coleman MP.

Neurobiol Aging. 2012 Mar;33(3):621.e1-621.e15. doi: 10.1016/j.neurobiolaging.2011.02.014. Epub 2011 Apr 13.

PMID:
21492964
33.

Dynamic association of tau with neuronal membranes is regulated by phosphorylation.

Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP.

Neurobiol Aging. 2012 Feb;33(2):431.e27-38. doi: 10.1016/j.neurobiolaging.2011.01.005. Epub 2011 Mar 8.

PMID:
21388709
34.

Isolation of detergent resistant microdomains from cultured neurons: detergent dependent alterations in protein composition.

Williamson R, Thompson AJ, Abu M, Hye A, Usardi A, Lynham S, Anderton BH, Hanger DP.

BMC Neurosci. 2010 Sep 22;11:120. doi: 10.1186/1471-2202-11-120.

35.

Tau cleavage and tau aggregation in neurodegenerative disease.

Hanger DP, Wray S.

Biochem Soc Trans. 2010 Aug;38(4):1016-20. doi: 10.1042/BST0381016. Review.

PMID:
20658996
36.

Functional implications of the association of tau with the plasma membrane.

Pooler AM, Hanger DP.

Biochem Soc Trans. 2010 Aug;38(4):1012-5. doi: 10.1042/BST0381012. Review.

PMID:
20658995
37.

Transgenic mouse models of tauopathy in drug discovery.

Noble W, Hanger DP, Gallo JM.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):403-28. Review.

PMID:
20522014
38.

Anti-inflammatory impact of minocycline in a mouse model of tauopathy.

Garwood CJ, Cooper JD, Hanger DP, Noble W.

Front Psychiatry. 2010 Oct 12;1:136. doi: 10.3389/fpsyt.2010.00136. eCollection 2010.

39.

Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease.

Hanger DP, Seereeram A, Noble W.

Expert Rev Neurother. 2009 Nov;9(11):1647-66. doi: 10.1586/ern.09.104. Review.

PMID:
19903024
40.

The microtubule-associated protein tau is also phosphorylated on tyrosine.

Lebouvier T, Scales TM, Williamson R, Noble W, Duyckaerts C, Hanger DP, Reynolds CH, Anderton BH, Derkinderen P.

J Alzheimers Dis. 2009;18(1):1-9. doi: 10.3233/JAD-2009-1116. Review.

PMID:
19542604
41.

Quantitation of glycogen synthase kinase-3 sensitive proteins in neuronal membrane rafts.

Thompson AJ, Williamson R, Schofield E, Stephenson J, Hanger D, Anderton B.

Proteomics. 2009 Jun;9(11):3022-35. doi: 10.1002/pmic.200900006.

PMID:
19526546
42.

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Noble W, Garwood CJ, Hanger DP.

Prion. 2009 Apr-Jun;3(2):78-83. Epub 2009 Apr 21. Review.

43.

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Hanger DP, Anderton BH, Noble W.

Trends Mol Med. 2009 Mar;15(3):112-9. doi: 10.1016/j.molmed.2009.01.003. Epub 2009 Feb 24. Review.

PMID:
19246243
44.

Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease.

Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH.

FASEB J. 2009 Mar;23(3):739-50. doi: 10.1096/fj.08-113795. Epub 2008 Nov 11.

PMID:
19001528
45.

Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin.

Cuchillo-Ibanez I, Seereeram A, Byers HL, Leung KY, Ward MA, Anderton BH, Hanger DP.

FASEB J. 2008 Sep;22(9):3186-95. doi: 10.1096/fj.08-109181. Epub 2008 May 29.

PMID:
18511549
46.

Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.

Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T, Zvelebil M, Yang A, Sheppard PW, Varndell IM, Hanger DP, Anderton BH.

J Biol Chem. 2008 Jun 27;283(26):18177-86. doi: 10.1074/jbc.M709715200. Epub 2008 May 8.

47.

Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.

Wray S, Saxton M, Anderton BH, Hanger DP.

J Neurochem. 2008 Jun 1;105(6):2343-52. doi: 10.1111/j.1471-4159.2008.05321.x.

48.

Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism.

Williamson R, Usardi A, Hanger DP, Anderton BH.

FASEB J. 2008 May;22(5):1552-9. Epub 2007 Dec 20.

PMID:
18096814
49.

The microtubule-associated protein tau is phosphorylated by Syk.

Lebouvier T, Scales TM, Hanger DP, Geahlen RL, Lardeux B, Reynolds CH, Anderton BH, Derkinderen P.

Biochim Biophys Acta. 2008 Feb;1783(2):188-92. Epub 2007 Nov 21.

50.

Kinase activities increase during the development of tauopathy in htau mice.

Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W.

J Neurochem. 2007 Dec;103(6):2256-67. Epub 2007 Oct 1.

Supplemental Content

Loading ...
Support Center